Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.58 |
| ▸ | NPY1R | P25929 | 9/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24147031 | 0.92 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL25867398 | 0.92 | CCKBR (0.48) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL18258324 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL25866171 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL24146579 | 0.91 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL24146766 | 0.90 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL24146761 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL24147032 | 0.89 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL26179135 | 0.88 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL25308138 | 0.87 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | NPY4R 822/4885NPY1R 1075/4885NPY5R 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.